Alpha Crest Capital Management LLC Allogene Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $352,696 - $590,561	34,176 Added 160.62%	55,454 $599,000
Q2 2022 Aug 11, 2022	SELL	$6.78 - $12.28 $191,846 - $347,474	-28,296 Reduced 57.08%	21,278 $243,000
Q1 2022 May 12, 2022	BUY	$7.65 - $15.29 $172,431 - $344,636	22,540 Added 83.38%	49,574 $452,000
Q4 2021 Feb 09, 2022	BUY	$13.13 - $24.52 $354,956 - $662,873	27,034 New	27,034 $403,000
Q3 2021 Nov 10, 2021	SELL	$21.01 - $27.64 $1.71 Million - $2.25 Million	-81,305 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$23.49 - $35.8 $1.53 Million - $2.33 Million	65,005 Added 398.8%	81,305 $2.12 Million
Q1 2021 May 13, 2021	BUY	$25.79 - $39.02 $126,371 - $191,198	4,900 Added 42.98%	16,300 $575,000
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $287,736 - $495,330	11,400 New	11,400 $288,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.